Aclarion's Q2 Loss Deepens to $2.75M, but $10.4M Raise Pushes Cash Runway into H2 2027

summarizeSummary

Aclarion's Q2 2026 loss widened to $2.75M as spending surged, but a $10.4M capital raise extended its cash runway into H2 2027. The company is fortifying its defenses against an activist takeover bid while revenue remains minimal.

check_boxKey Events · Earnings and Guidance · ACON

• Q2 Net Loss Widens to $2.75M

  The net loss grew to $2.75M from $1.60M a year ago, driven by a near-doubling of operating expenses to $2.9M as the company ramped sales hiring and legal spending.

• Cash Runway Extended to H2 2027

  Cash and equivalents stood at $16.3M at quarter-end, following a $10.4M registered direct offering in January 2026. Management believes this funds operations into the second half of 2027.

• Revenue Remains Minimal at $25K

  Quarterly revenue was just $25,208, up 30% year-over-year but still negligible against a $5.8M market cap. The company is pre-revenue for practical purposes.

• 499,000 RSUs Granted to Insiders

  The board granted 499,000 restricted stock units to executives, employees, and directors, vesting in June 2027. This represents potential dilution of roughly 17% of the current outstanding share count.

auto_awesomeAnalysis · ACON · Industrial Applications And Services

Operating cash burn hit $5.3M in the first half of 2026, yet the $10.4M January offering bolstered cash to $16.3M—enough to fund operations into the second half of 2027. Revenue remains negligible at $25K for the quarter, while operating expenses nearly doubled year-over-year to $2.9M, fueled by aggressive sales hiring and legal costs tied to activist defense. The board also adopted a poison pill and authorized a $2.5M buyback, signaling it is digging in against Echo Lake Capital's rejected $4.00/share takeover bid. The massive 499,000-share RSU grant to insiders—vesting in June 2027—aligns management with long-term survival but adds dilution overhang.